#M&A – Page 2 – HEALTHCARE INSIGHTS

Key Development U.S. commercial biopharmaceutical specialists Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Pharmaceuticals (NASDAQ: INDV) have formally entered into a... Read more

Tag: #M&A

Rare Skeletal Disease M&A: BioMarin Acquires Alesta Therapeutics for Up to $490 Million to Challenge AstraZeneca’s Hypophosphatasia Franchise with Oral Asset ALE1

Rare Genetic Dermatology Licensing: LEO Pharma Secures Worldwide Exclusive Rights to Oral Dersimelagon for Up to $435 Million from Mitsubishi Tanabe Pharma

Targeted Radiopharmaceuticals & Rare Epilepsy M&A: Jazz Pharmaceuticals Executes $1.32 Billion Acquisition of Actio Biosciences to Acquire First-in-Class Pediatric Precision Therapy

Biopharmaceutical M&A: Biogen Completes Acquisition of RayThera Inc., Expanding Immunology Pipeline with Small-Molecule Assets

Consumer Health & Wellness M&A: Procter & Gamble (P&G) Executes $3.8 Billion Acquisition of Premium Supplement Brand Thorne HealthTech

In Vivo Cell Therapy Breakthrough: Johnson & Johnson Commits $785 Million Upfront to Sail Biomedicines, Securing a $2.58 Billion Acquisition Option for Autoimmune CAR-T Platform

Mega Radiopharmaceutical Merger: Curium Strikes $8 Billion Deal to Acquire Rival Lantheus, Building a Global Theranostics Powerhouse

Neuroscience Consolidation: Supernus and Indivior Agree to All-Stock Merger Creating a $2.2 Billion CNS Biopharma Powerhouse

Billion-Dollar MedTech Buyout: KKR Executes $5.7 Billion All-Cash Take-Private Transaction for Integer Holdings

Facebook

Map

Online Members